Entresto Tablet, Film Coated
Product Images NDC 71610-807

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Entresto (NDC 71610-807). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

71610-807-37 (71610 807 37)

71610-807-37 (71610 807 37)
This text is not-readable.*
FDA Label Image

Aphena (Aphena)

Aphena (Aphena)
FDA Label Image

Valsartan Structural Formula (Entresto 01)

Valsartan Structural Formula (Entresto 01)
FDA Label Image

Figure 1: Effect Of Entresto On Pharmacokinetics Of Coadministered Drugs (Entresto 02)

Figure 1: Effect Of Entresto On Pharmacokinetics Of Coadministered Drugs (Entresto 02)
This is not a readable text.*
FDA Label Image

Figure 2: Pharmacokinetics Of Entresto In Specific Populations (Entresto 03)

Figure 2: Pharmacokinetics Of Entresto In Specific Populations (Entresto 03)
FDA Label Image

Figure 3: Kaplan-meier Curves For The Primary Composite Endpoint (a), Cardiovascular Death (b), And Heart Failure Hospitalization (c) (Entresto 04)

Figure 3: Kaplan-meier Curves For The Primary Composite Endpoint (a), Cardiovascular Death (b), And Heart Failure Hospitalization (c) (Entresto 04)
FDA Label Image

Figure 4: Primary Composite Endpoint (cv Death Or Hf Hospitalization) (Subgroup Analysis)

Figure 4: Primary Composite Endpoint (cv Death Or Hf Hospitalization) (Subgroup Analysis)
This is a dataset containing various demographic and health-related information such as age, gender, weight, race, region, NYHA class, estimated GFR, diabetes status, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP levels, hypertension status, prior medication use, prior hospitalization for heart failure, time since diagnosis, cause of heart failure, and presence of ICD including CRT-D. Additionally, there are numbers related to the use of medications like Entresto and Enalapril, showing the percentage of participants falling into different categories or experiencing different outcomes. The dataset also includes hazard ratios with confidence intervals comparing the efficacy of Entresto and Enalapril.*
FDA Label Image

Figure 5: Mean Number Of Events Over Time For The Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death (Entresto 09)

Figure 5: Mean Number Of Events Over Time For The Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death (Entresto 09)
FDA Label Image

Figure 6: Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death – Subgroup Analysis (paragon-hf) (Entresto 10)

Figure 6: Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death – Subgroup Analysis (paragon-hf) (Entresto 10)
FDA Label Image

Figure 7: Treatment Effect For The Composite Endpoint Of Time To First Hf Hospitalization Or Cv Death By Lvef In Paradigm-hf And Paragon-hf (Entresto 11)

Figure 7: Treatment Effect For The Composite Endpoint Of Time To First Hf Hospitalization Or Cv Death By Lvef In Paradigm-hf And Paragon-hf (Entresto 11)
This is useful information comparing hazard ratios for PARADIGM-HF and PARAGON-HF clinical trials evaluating the use of ENTRESTO against enalapril and valsartan, respectively. The diagram displays left ventricular ejection fraction at screening (%) along with hazard ratios for different scenarios.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.